Tenaya Therapeutics, Inc. (TNYA)
| Market Cap | 154.74M -13.7% |
| Revenue (ttm) | 1.34M |
| Net Income | -103.12M |
| EPS | -0.53 |
| Shares Out | 224.23M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,112,529 |
| Open | 0.7010 |
| Previous Close | 0.6952 |
| Day's Range | 0.6869 - 0.7036 |
| 52-Week Range | 0.5316 - 2.3500 |
| Beta | 2.79 |
| Analysts | Strong Buy |
| Price Target | 3.20 (+363.7%) |
| Earnings Date | Aug 5, 2026 |
About TNYA
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for TNYA stock is "Strong Buy." The 12-month stock price target is $3.2, which is an increase of 363.70% from the latest price.
News
Tenaya Therapeutics Transcript: Canaccord Genuity's 46th Annual Growth Conference
The company is advancing a diversified pipeline targeting heart disease, with gene therapies TN-201 and TN-401 showing strong efficacy and safety, and the small molecule TN-301 re-entering development. Key regulatory and clinical updates, as well as financial clarity, are expected in Q4.
Tenaya Therapeutics reports Q2 EPS (20c), consensus (7c)
Reports Q2 revenue $1.11M, consensus $10M. The increase in net loss was primarily due to a $21.8M non-cash impairment charge related to the early termination of the company’s Union City…
Tenaya Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Positive Interim Data Shared in 2Q 2026 from the MyPEAK™-1 and RIDGE™-1 Clinical Trials Each Demonstrated Meaningful Improvements in Key Disease Characteristics Additional Data Releases Plus Updates o...
Tenaya Therapeutics Quarterly report: Q2 2026
Tenaya Therapeutics has published its Q2 2026 quarterly earnings report on August 5, 2026.
Tenaya Therapeutics Earnings release: Q2 2026
Tenaya Therapeutics released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Tenaya Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference
SOUTH SAN FRANCISCO, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentia...
Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potential...
Tenaya Therapeutics appoints Eric Hyllengren as CFO
Tenaya Therapeutics (TNYA) announced the appointment of Eric Hyllengren as CFO, effective July 13. In this role, he will oversee financial strategy, capital allocation, investor relations and corporat...
Tenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer
Experienced Industry Leader Brings Two Decades of Finance, Strategic and Operational Expertise Experienced Industry Leader Brings Two Decades of Finance, Strategic and Operational Expertise
Tenaya Therapeutics Transcript: Jefferies Global Healthcare Conference 2026
Focused on innovative therapies for heart disease, the company reported strong early clinical data for two gene therapies and a promising small molecule, with favorable safety and regulatory momentum. Key data readouts and regulatory updates are expected in the second half of the year.
Tenaya Therapeutics Slides: FY 2026
Tenaya Therapeutics has posted slides in relation to its FY 2026 quarterly earnings report, which was published on June 4, 2026.
Tenaya Therapeutics management to meet with Piper Sandler
Meeting to be held in New York on June 4 hosted by Piper Sandler.
Tenaya Therapeutics Transcript: Study result
Interim results from the MyPEAK-1 trial of TN-201 gene therapy in MYBPC3-associated HCM show sustained improvements in cardiac structure, symptom burden, and functional capacity, especially at higher doses. Safety remains favorable, and regulatory designations support accelerated development for both adult and pediatric populations.
Tenaya Therapeutics Press release: Study result
Tenaya Therapeutics issued a press release on June 3, 2026, disclosing material business information to investors.
Tenaya Therapeutics Slides: Study result
Tenaya Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 3, 2026.
Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Symptoms
All Evaluable Patients Achieved Improvements in Multiple Hallmarks of MYBPC3-Associated HCM Benefits Among Cohort 1 Patients Sustained as Far Out as Two Years; Cohort 2 Patients Showed Greater Sympto...
Tenaya Therapeutics to Announce New Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026
SOUTH SAN FRANCISCO, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentia...
Tenaya Therapeutics to Participate in the Jefferies Global Healthcare Conference 2026
SOUTH SAN FRANCISCO, Calif., May 29, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potential...
Tenaya Therapeutics Transcript: Study update
Interim results from the RIDGE-1 trial show TN-401 gene therapy led to consistent, durable reductions in arrhythmia burden and was well tolerated at both tested doses in PKP2-associated ARVC patients. Biopsies confirmed robust gene delivery and expression, supporting TN-401's disease-modifying potential.
Tenaya Therapeutics Press release: Study update
Tenaya Therapeutics issued a press release on May 15, 2026, disclosing material business information to investors.
Tenaya Therapeutics Slides: Study update
Tenaya Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on May 15, 2026.
Tenaya reports data from RIDGE-1 Phase 1b/2 clinical trial of TN-401
Tenaya Therapeutics (TNYA) presented interim data from the ongoing RIDGE-1 Phase 1b/2 clinical trial of TN-401 gene therapy at the American Society of Gene and Cell Therapies, or ASGCT, 2026…
Positive Interim Data from Cohorts 1 and 2 of Tenaya's RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Demonstrated Consistent Reductions in Arrhythmia Burden for Adults with PKP2-associated ARVC
All Patients Achieved Meaningful Decreases (Mean = 64%) in Daily Premature Ventricular Contraction Count TN-401 Gene Therapy was Well Tolerated at 3E13 vg/kg and 6E13 vg/kg Doses Post-dose Biopsies P...
Tenaya Therapeutics reports Q1 EPS (9c), consensus (9c)
Reports Q1 revenue $225,000, consensus $7.5M. “We are entering a catalyst-rich period for Tenaya, with multiple clinical milestones expected across our lead gene therapy programs throughout 2026. Buil...
Tenaya Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
One-Year Cohort 1 Data and Initial Cohort 2 Data from RIDGE™-1 Phase 1b/2 Trial of TN-401 for PKP2-Associated ARVC to be Presented at ASGCT 2026 New Data from Both Cohorts of the MyPEAK™-1 Phase 1b/2 ...